Related Experiment Video

Updated: Aug 8, 2026

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method
16:07

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method

Published on: September 16, 2017

Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes

E P Sampaio1, E N Sarno, R Galilly

  • 1Laboratory of Cellular Physiology and Immunology, Rockefeller University, New York, New York 10021.

The Journal of Experimental Medicine
|March 1, 1991
PubMed

Insights

Thalidomide selectively reduces tumor necrosis factor alpha (TNF-alpha) production in monocytes. This targeted inhibition, observed at clinical doses, suggests potential for understanding and managing TNF-alpha

Area of Science:

  • Immunology
  • Pharmacology

Background:

  • Tumor necrosis factor alpha (TNF-alpha) is a key inflammatory cytokine.
  • Dysregulation of TNF-alpha is implicated in various diseases.
  • Thalidomide is a known immunomodulatory drug.

Purpose of the Study:

  • To investigate the selective effect of thalidomide on TNF-alpha production in human monocytes.
  • To determine the concentration-dependent inhibition of TNF-alpha by thalidomide.
  • To assess the impact of thalidomide on other monocyte-derived cytokines.

Main Methods:

  • Human monocytes were cultured and stimulated with lipopolysaccharide and other agonists.
  • Thalidomide was added at clinically relevant concentrations (1 microgram/ml).
  • TNF-alpha levels were measured; total protein and other cytokine levels (IL-1 beta, IL-6, GM-CSF) were assessed.

Main Results:

  • Thalidomide selectively inhibited TNF-alpha production by approximately 40% at 1 microgram/ml.
  • Total protein synthesis and the production of IL-1 beta, IL-6, and GM-CSF remained unaffected.
  • The drug demonstrated a specific inhibitory action on TNF-alpha.

Conclusions:

  • Thalidomide selectively suppresses monocyte TNF-alpha production.
  • This selectivity offers a potential therapeutic window for modulating TNF-alpha in vivo.
  • Further research can explore thalidomide's role in conditions associated with elevated TNF-alpha.

More Related Videos

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity07:09

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity

Published on: January 7, 2019

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.